The Era of Provisional Stenting for Bifurcations Comes to an End

After the large studies which set provisional stenting as the preferred strategy to treat bifurcations comes the double kissing crush technique (DK crush) to break the mold once again. This time, the DK crush technique is tested against provisional stenting in the left main, with a 3-year follow-up.

Técnica Doble Crush Doble Kissing vs. stent provisional

The DKCRUSH-V, soon to be published in J Am Coll Cardiol Intv, randomized 482 patients with unprotected left main stenosis to DK crush vs provisional stenting and followed them up to 3 years. Primary end point was target vessel failure (death, target vessel MI and target vessel revascularization). Safety end point was stent thrombosis. Patients were classified according to lesion complexity using the Syntax score, among others.

After 3 years, target vessel failure rate occurred in 16.9% of the provisional stent group vs. 8.3% in the DK crush group (p=0.005). This difference was mainly driven by a higher rate of target vessel MI (5.8% vs 1.7%; p=0.017) and higher target vessel revascularization rate (10.3% vs 5%; p=0.029) in the provisional stenting arm. 


Read also: TAVR Offers Better Quality of Life to Low Risk Patients.


Definite or probable thrombosis at 3 years resulted 4.1% for the provisional stenting arm and 0.4% for the DK crush arm (0.006). 

It is worth mentioning that DK crush was associated with a significant reduction both in the efficacy and safety end points in unprotected left main complex lesions.

Conclusion

The provisional stenting technique to treat left main lesions resulted in more target vessel MI, more target vessel revascularization and more stent thrombosis compared against the double kissing crush technique. This is the first of several randomized studies needed to gather definite evidence. 

Original Title: Three-Year Outcomes of the DKCRUSH-V Trial Comparing DK Crush With Provisional Stenting for Left Main Bifurcation Lesions.

Reference: Xiang Chen et al. J Am Coll Cardiol Intv 2019. Online before print.



Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....